A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 1017-1024

  Turpeinen, Miia ^a,c,d   Hofmann, Ute ^a   Klein, Kathrin ^a   Murdter, Thomas ^a   Schwab, Matthias ^a,b   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF OULU   (Finland)

^d Institute of Clinical Genetics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; NABUMETONE; NAPROXEN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; BIOTRANSFORMATION; BLOTTING, WESTERN; BUTANONES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; NADP; NAPHTHALENEACETIC ACIDS; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 66449130636     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025700     Document Type: Article

References (37)

1. Chauret N, Gauthier A, and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4.
2. Dahl SL (1993) Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug. Ann Pharmacother 27:456-463.
3. Dailly E, Urien S, Chanut E, Claudel B, Guerra N, Fernandez C, Jolliet P, and Bourin M (2002) Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry 26:699-703.
4. Davies NM (1997) Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo- oxygenase-2 inhibition? Clin Pharmacokinet 33:404-416.
5. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
6. Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD, and Guchelaar HJ (2003) CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 20:451-457.
7. Gunes A and Dahl ML (2008) Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9:625-637.
8. Haddock RE, Jeffery DJ, Lloyd JA, and Thawley AR (1984) Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327-337.
9. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, and Ekbom A (2004) Nabum- etone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315-2343; discussion 2344-2345.
10. Hyneck ML (1992) An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol Suppl 36:20-24.
11. Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, and Bates DW (2007) Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf 2:177-185.
12. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332-337.
13. Kumpulainen H, Mahonen N, Laitinen ML, Jaurakkajarvi M, Raunio H, Juvonen RO, Vep-saalaainen J, Jaarvinen T, and Rautio J (2006) Evaluation of hydroxyimine as cytochrome
14. P450-selective prodrug structure. J Med Chem 49:1207-1211.
15. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649 -656.
16. Lang T, Klein K, Fischer J, Nuassler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399 -415.
17. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
18. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
19. Lee CA, Neul D, Clouser-Roche A, Dalvie D, and Totah RA (2008) Identification of substrates for metabolism by human CYP2J2 enzyme. Drug Metab Rev 40 (S):215.
20. Nobilis M, Kopecky J, Kvetina J, Svoboda Z, Pour M, Kunes J, Holcapek M, and KolarovaL (2003) Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J Pharm Biomed Anal 32:641-656.
21. Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, et al. (2001) CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 21:398 -407.
22. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
23. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
24. Richter T, Muardter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlo- pidine. J Pharmacol Exp Ther 308:189-197.
25. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
26. Rothstein R (1998) Safety profiles of leading nonsteroidal anti-inflammatory drugs. Am J Med 105:39S-43S.
27. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, and Goldstein JA (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239 -249.
28. Suzuki H, Kneller MB, Haining RL, Trager WF, and Rettie AE (2002) (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235-239.
29. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cyto- chromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
30. Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, and Zanger UM (2006) A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet Genomics 16:767-770.
31. Turpeinen M, Raunio H, and Pelkonen O (2006) The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7:705-714.
32. Turpeinen M, Uusitalo J, Jouko U, Jalonen J, Jorma J, Pelkonen O, and Olavi P (2005) Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123-132.
33. Walsky RL and Obach RS (2007) A comparison of 2-phenyl-2-(1-piperidinyl) propane (ppp), 1,1',1"-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35:2053-2059.
34. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
35. Wolbold R, Klein K, Burk O, Nuassler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978 -988.
36. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759.
37. Zanger UM, Turpeinen M, Klein K, and Schwab M (2008) Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.